Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus platinum chemotherapy as neoadjuvant therapy in locally advanced cervical cancer
ChiCTR2200065392Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in Cervical Cancer (CC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Pathological complete response rate. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2200065392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065392.